Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | MMP13 | P45452 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CRHBP | P24387 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.65 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2937839 | 0.90 | ALDH1A1 (0.65) | SMN1; SMN2RAB9ANPC1HPGDALDH1A1 | |
| SCHEMBL179085 | 0.88 | RAB9A (0.76) | SMN1; SMN2RAB9ANPC1HPGDALDH1A1 | |
| SCHEMBL179082 | 0.85 | HPGD (0.73) | SMN1; SMN2RAB9ANPC1HPGDALDH1A1 | |
| SCHEMBL7322125 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2RAB9ANPC1HPGDALDH1A1 | |
| SCHEMBL4991673 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2RAB9ANPC1HPGDALDH1A1 | |
| SCHEMBL5815420 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2RAB9ANPC1HPGDALDH1A1 | |
| SCHEMBL19030884 | 0.84 | SMN1; SMN2 (0.58) | SMN1; SMN2RAB9ANPC1HPGDALDH1A1 | |
| SCHEMBL179025 | 0.84 | HPGD (0.84) | SMN1; SMN2RAB9ANPC1HPGDALDH1A1 | |
| SCHEMBL2730357 | 0.84 | ALDH1A1 (0.62) | SMN1; SMN2RAB9ANPC1ALDH1A1TDP1 | |
| SCHEMBL179079 | 0.84 | ALDH1A1 (0.70) | SMN1; SMN2RAB9ANPC1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0269650-A1 | SYNTHESIS OF ANTIULCER COMPOUNDS | RECORDATI FARMA SRL (IT) | 1988-06-08 | — | — | EP | claimed |
| WO-1987005902-A1 | SYNTHESIS OF ANTIULCER COMPOUNDS | RECORDATI FARMA SRL (IT) | 1987-10-08 | — | — | WO | claimed |
| EP-3452477-B1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B C I PHARMA (BE) | 2023-09-13 | — | — | EP | disclosed |
| EP-2593079-B1 | MENTHYL CARBAMATE COMPOUNDS AS SKIN AND/OR HAIR LIGHTENING ACTIVES | SYMRISE AG (DE) | 2016-11-16 | — | — | EP | disclosed |
| US-9060949-B2 | Menthyl carbamate compounds as skin and/or hair lightening actives | SYMRISE AG (DE) | 2015-06-23 | — | — | US | disclosed |
| US-20130129646-A1 | MENTHYL CARBAMATE COMPOUNDS AS SKIN AND/OR HAIR LIGHTENING ACTIVES | SYMRISE AG (DE) | 2013-05-23 | — | — | US | disclosed |
| EP-1836163-B1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
| US-20080249075-A1 | C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| US-6967196-B1 | Sulfonamide compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | REN, ACE, PEPD | SMN1; SMN2 2748/4885RAB9A 287/4885NPC1 4017/4885 |
| US-20130129646-A1 | MENTHYL CARBAMATE COMPOUNDS AS SKIN AND/OR HAIR LIGHTENING ACTIVES | TYR, CRAT, SUCLG1 | SMN1; SMN2 4666/4885RAB9A 3830/4885NPC1 3818/4885 |
| US-20080249075-A1 | C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds | HSD17B11, CYP19A1, ESRRA | SMN1; SMN2 2292/4885RAB9A 1020/4885NPC1 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.